ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » California » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in California

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
RAMIN MANSHADI MD

Cardiovascular Disease

8,759

$1.01M

765
554 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 28%

$115
Average prescription price

Avg: $67

MANUEL AGUILERA M.D.

Cardiovascular Disease

13,650

$985K

473
427 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

6%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$72
Average prescription price

Avg: $67

GARO PEHLEVANIAN M.D.

Cardiovascular Disease

9,819

$980K

228
206 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

56%
prescriptions for brand name drugs

Avg: 28%

$100
Average prescription price

Avg: $67

TRI NGUYEN M.D.

Cardiovascular Disease

12,772

$971K

919
839 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$76
Average prescription price

Avg: $67

MOHAMED KHAN M.D.

Cardiovascular Disease

13,758

$958K

1295
1043 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 28%

$70
Average prescription price

Avg: $67

RAJIV PUNJYA M.D.

Cardiovascular Disease

14,041

$952K

1133
964 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 28%

$68
Average prescription price

Avg: $67

RAVEEN ARORA M.D.

Cardiovascular Disease

9,051

$924K

381
337 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

49%
prescriptions for brand name drugs

Avg: 28%

$102
Average prescription price

Avg: $67

OSCAR ZAMBRANO M.D.

Cardiovascular Disease

22,733

$918K

1008
870 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

12%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 28%

$40
Average prescription price

Avg: $67

HUGO RIFFEL DALINGER MD

Cardiovascular Disease

11,987

$910K

775
740 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 28%

$76
Average prescription price

Avg: $67

ROLLINGTON FERGUSON MD

Cardiovascular Disease

12,011

$907K

546
325 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

26%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 28%

$75
Average prescription price

Avg: $67

TERESA DE MARCO MD

Cardiovascular Disease

1,402

$903K

138
59 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 28%

$644
Average prescription price

Avg: $67

BENJAMIN POTKIN M.D.

Cardiovascular Disease

14,966

$890K

1064
934 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 28%

$59
Average prescription price

Avg: $67

IRAJ DARDASHTI MD

Cardiovascular Disease

13,224

$889K

475
458 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

43%
prescriptions for brand name drugs

Avg: 28%

$67
Average prescription price

Avg: $67

AVINASH MONDKAR M.D.

Cardiovascular Disease

8,350

$885K

435
401 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

9%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$106
Average prescription price

Avg: $67

HAROUTIOUN MESROBIAN M.D.

Cardiovascular Disease

14,585

$883K

655
588 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$61
Average prescription price

Avg: $67

EDGAR ALEMAN MD

Cardiovascular Disease

13,340

$866K

763
738 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$65
Average prescription price

Avg: $67

KARL VOGELBACH MD

Cardiovascular Disease

8,671

$859K

468
442 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

53%
prescriptions for brand name drugs

Avg: 28%

$99
Average prescription price

Avg: $67

JOHN CHIN MD

Cardiovascular Disease

6,186

$849K

404
312 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 28%

$137
Average prescription price

Avg: $67

MICHAEL GEN M.D.

Cardiovascular Disease

11,862

$847K

887
764 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$71
Average prescription price

Avg: $67

DAREL BENVENUTI MD

Cardiovascular Disease

9,194

$845K

929
886 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 28%

$92
Average prescription price

Avg: $67

ROHIT SUNDRANI M.D.

Cardiovascular Disease

12,038

$829K

918
783 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$69
Average prescription price

Avg: $67

SANTOS UY MD

Cardiovascular Disease

9,462

$814K

383
367 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

41%
prescriptions for brand name drugs

Avg: 28%

$86
Average prescription price

Avg: $67

JEROME ROBINSON MD

Cardiovascular Disease

11,728

$811K

362
301 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$69
Average prescription price

Avg: $67

JIGNESH PATEL MD PHD

Cardiovascular Disease

4,637

$809K

373
237 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 28%

$174
Average prescription price

Avg: $67

ALBERT SHARF MD

Cardiovascular Disease

16,547

$805K

807
683 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 28%

$49
Average prescription price

Avg: $67

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank